{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:54:00Z","timestamp":1792133640251,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,24]]},"DOI":"10.7759\/cureus.30638","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T18:43:35Z","timestamp":1666637015000},"source":"Crossref","is-referenced-by-count":6,"title":["Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management"],"prefix":"10.7759","author":[{"given":"Adeel S","family":"Zubair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim M","family":"Baehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger AF","year":"2016","unstructured":"Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016, 29:806-12. 10.1097\/WCO.0000000000000391","journal-title":"Curr Opin Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system","volume":"11","author":"Dalakas MC","year":"2018","unstructured":"Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord. 2018, 11:1756286418799864. 10.1177\/1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira A","year":"2019","unstructured":"Moreira A, Loquai C, Pf\u00f6hler C, et al.. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 2019, 106:12-23. 10.1016\/j.ejca.2018.09.033","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy","volume":"152","author":"Duong SL","year":"2021","unstructured":"Duong SL, Barbiero FJ, Nowak RJ, Baehring JM. Neurotoxicities associated with immune checkpoint inhibitor therapy. J Neurooncol. 2021, 152:265-77. 10.1007\/s11060-021-03695-w","journal-title":"J Neurooncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini A","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, Vogrig A. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021, 96:754-66. 10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus NE","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJ. Myasthenia gravis. Nat Rev Dis Primers. 2019, 5:30. 10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015, 14:1023-36. 10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116830","article-title":"Exploring outcomes and characteristics of myasthenia gravis: rationale, aims and design of registry - The EXPLORE-MG registry","volume":"414","author":"Anil R","year":"2020","unstructured":"Anil R, Kumar A, Alaparthi S, et al.. Exploring outcomes and characteristics of myasthenia gravis: rationale, aims and design of registry - The EXPLORE-MG registry. J Neurol Sci. 2020, 414:116830. 10.1016\/j.jns.2020.116830","journal-title":"J Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr AS","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010, 10:46. 10.1186\/1471-2377-10-46","journal-title":"BMC Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: new case and literature review","volume":"27","author":"Gonzalez NL","year":"2017","unstructured":"Gonzalez NL, Puwanant A, Lu A, Marks SM, \u017divkovi\u0107 SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017, 27:266-8. 10.1016\/j.nmd.2017.01.002","journal-title":"Neuromuscul Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau KH","year":"2016","unstructured":"Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016, 54:157-61. 10.1002\/mus.25141","journal-title":"Muscle Nerve"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients","volume":"27","author":"Nguyen BH","year":"2017","unstructured":"Nguyen BH, Kuo J, Budiman A, Christie H, Ali S. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res. 2017, 27:152-4. 10.1097\/CMR.0000000000000310","journal-title":"Melanoma Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki S","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, et al.. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017, 89:1127-34. 10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens CJ","year":"2013","unstructured":"Voskens CJ, Goldinger SM, Loquai C, et al.. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013, 8:e53745. 10.1371\/journal.pone.0053745","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2020.05.004","article-title":"Immune checkpoint inhibitor-mediated myasthenia gravis","volume":"59","author":"Ho AK","year":"2020","unstructured":"Ho AK, Cooksley T. Immune checkpoint inhibitor-mediated myasthenia gravis. J Emerg Med. 2020, 59:561-2. 10.1016\/j.jemermed.2020.05.004","journal-title":"J Emerg Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi RR","year":"2019","unstructured":"Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019, 60:693-9. 10.1002\/mus.26689","journal-title":"Muscle Nerve"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob D","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008, 37:141-9. 10.1002\/mus.20950","journal-title":"Muscle Nerve"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315656","article-title":"A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy","volume":"237","author":"Mantegazza R","year":"1990","unstructured":"Mantegazza R, Beghi E, Pareyson D, et al.. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol. 1990, 237:339-44. 10.1007\/BF00315656","journal-title":"J Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber JS","year":"2015","unstructured":"Weber JS, D'Angelo SP, Minor D, et al.. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015, 16:375-84. 10.1016\/S1470-2045(15)70076-8","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al.. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015, 372:2521-32. 10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O'Day SJ","year":"2010","unstructured":"O'Day SJ, Maio M, Chiarion-Sileni V, et al.. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010, 21:1712-7. 10.1093\/annonc\/mdq013","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang YT","year":"2020","unstructured":"Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020, 11:634. 10.3389\/fneur.2020.00634","journal-title":"Front Neurol"},{"key":"ref25","article-title":"Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis","volume":"78","author":"Maeda O","year":"2016","unstructured":"Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 2016, 78:119-22.","journal-title":"Nagoya J Med Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2018.06.003","article-title":"Immune checkpoint-mediated myositis and myasthenia gravis: a case report and review of evaluation and management","volume":"39","author":"Kang KH","year":"2018","unstructured":"Kang KH, Grubb W, Sawlani K, et al.. Immune checkpoint-mediated myositis and myasthenia gravis: a case report and review of evaluation and management. Am J Otolaryngol. 2018, 39:642-5. 10.1016\/j.amjoto.2018.06.003","journal-title":"Am J Otolaryngol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25496","article-title":"A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma","volume":"55","author":"Alnahhas I","year":"2017","unstructured":"Alnahhas I, Wong J. A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma. Muscle Nerve. 2017, 55:E25-6. 10.1002\/mus.25496","journal-title":"Muscle Nerve"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson JA","year":"2019","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al.. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw. 2019, 17:255-89. 10.6004\/jnccn.2019.0013","journal-title":"J Natl Compr Canc Netw"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0398-y","article-title":"Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis","volume":"13","author":"Guptill JT","year":"2016","unstructured":"Guptill JT, Soni M, Meriggioli MN. Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurotherapeutics. 2016, 13:118-31. 10.1007\/s13311-015-0398-y","journal-title":"Neurotherapeutics"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.36.5.729","article-title":"Prednisone-induced worsening of neuromuscular function in myasthenia gravis","volume":"36","author":"Miller RG","year":"1986","unstructured":"Miller RG, Milner-Brown HS, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology. 1986, 36:729-32. 10.1212\/wnl.36.5.729","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical predictors of steroid-induced exacerbation in myasthenia gravis","volume":"13","author":"Bae JS","year":"2006","unstructured":"Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci. 2006, 13:1006-10. 10.1016\/j.jocn.2005.12.041","journal-title":"J Clin Neurosci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos P","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997, 41:789-96. 10.1002\/ana.410410615","journal-title":"Ann Neurol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth D","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011, 76:2017-23. 10.1212\/WNL.0b013e31821e5505","journal-title":"Neurology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman L","year":"2007","unstructured":"Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007, 68:837-41. 10.1212\/01.wnl.0000256698.69121.45","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer N","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, et al.. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol. 2016, 263:1473-94. 10.1007\/s00415-016-8045-z","journal-title":"J Neurol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12261","article-title":"Glucocorticoids in myasthenia gravis - if, when, how, and how much?","volume":"130","author":"Hoffmann S","year":"2014","unstructured":"Hoffmann S, Kohler S, Ziegler A, Meisel A. Glucocorticoids in myasthenia gravis - if, when, how, and how much?. Acta Neurol Scand. 2014, 130:211-21. 10.1111\/ane.12261","journal-title":"Acta Neurol Scand"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000807","article-title":"Lambert-Eaton myasthenic syndrome, botulism, and immune checkpoint inhibitor-related myasthenia gravis","volume":"25","author":"Guidon AC","year":"2019","unstructured":"Guidon AC. Lambert-Eaton myasthenic syndrome, botulism, and immune checkpoint inhibitor-related myasthenia gravis. Continuum (Minneap Minn). 2019, 25:1785-806. 10.1212\/CON.0000000000000807","journal-title":"Continuum (Minneap Minn)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje AT","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K, et al.. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018, 124:3706-14. 10.1002\/cncr.31629","journal-title":"Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.03.006","article-title":"Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis","volume":"113","author":"Tedbirt B","year":"2019","unstructured":"Tedbirt B, De Pontville M, Branger P, et al.. Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis. Eur J Cancer. 2019, 113:72-4. 10.1016\/j.ejca.2019.03.006","journal-title":"Eur J Cancer"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious D","year":"2017","unstructured":"Makarious D, Horwood K, Coward JI. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017, 82:128-36. 10.1016\/j.ejca.2017.05.041","journal-title":"Eur J Cancer"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli MN","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009, 8:475-90. 10.1016\/S1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura T","year":"2016","unstructured":"Kimura T, Fukushima S, Miyashita A, et al.. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016, 107:1055-8. 10.1111\/cas.12961","journal-title":"Cancer Sci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao B","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014, 16:589-93. 10.1093\/neuonc\/nou001","journal-title":"Neuro Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1416-1","article-title":"Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report","volume":"19","author":"Kamo H","year":"2019","unstructured":"Kamo H, Hatano T, Kanai K, et al.. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. BMC Neurol. 2019, 19:184. 10.1186\/s12883-019-1416-1","journal-title":"BMC Neurol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.02.013","article-title":"Immune checkpoint inhibitors (ICIs)-related ocular myositis","volume":"30","author":"Garibaldi M","year":"2020","unstructured":"Garibaldi M, Calabr\u00f2 F, Merlonghi G, et al.. Immune checkpoint inhibitors (ICIs)-related ocular myositis. Neuromuscul Disord. 2020, 30:420-3. 10.1016\/j.nmd.2020.02.013","journal-title":"Neuromuscul Disord"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas N","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020, 9:e013757. 10.1161\/JAHA.119.013757","journal-title":"J Am Heart Assoc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/120706-myasthenia-gravis-in-the-setting-of-immune-checkpoint-inhibitor-therapy-practical-considerations-and-opinion-based-approach-to-acute-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:42:27Z","timestamp":1707507747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/120706-myasthenia-gravis-in-the-setting-of-immune-checkpoint-inhibitor-therapy-practical-considerations-and-opinion-based-approach-to-acute-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.30638","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,24]]}}}